PropertyValue
?:definition
  • An immunotherapy regimen consisting of pembrolizumab that may be used in the treatment of anal carcinoma; bladder, gastric, bone, colorectal, cervical, lung, penile, testicular, prostate, hepatobiliary, endometrial, and vulvar cancers; chronic lymphocytic leukemia (CLL); small lymphocytic lymphoma (SLL); diffuse large B-cell lymphoma (DLBCL); and cutaneous melanoma.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C5204945_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C5204945_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all